While life sciences M&A activity surges in today’s markets, the shift in regulatory enforcement priorities, constant innovation in technology, and strategic growth opportunities are changing the way dealmakers are approaching...more
It’s no secret that Democrats are traditionally trustbusters, but the Biden Administration is taking things to a whole new level, bringing novel—and arguably weak—cases that nonetheless slow or block tie-ups among healthcare...more
12/13/2023
/ Acquisitions ,
Antitrust Division ,
Biden Administration ,
Competition ,
Enforcement ,
Federal Trade Commission (FTC) ,
Healthcare ,
Healthcare Facilities ,
Hospitals ,
Medical Devices ,
Mergers ,
Pharmaceutical Industry ,
Regulatory Agenda ,
Regulatory Reform